Compare TORO & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TORO | MDWD |
|---|---|---|
| Founded | 2022 | 2000 |
| Country | Cyprus | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.8M | 181.1M |
| IPO Year | 2022 | 2013 |
| Metric | TORO | MDWD |
|---|---|---|
| Price | $4.97 | $14.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 33.7K | ★ 80.8K |
| Earning Date | 04-15-2026 | 05-20-2026 |
| Dividend Yield | ★ 36.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $48.92 |
| Revenue Next Year | N/A | $35.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.16 | $13.54 |
| 52 Week High | $8.50 | $21.26 |
| Indicator | TORO | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 48.72 |
| Support Level | $4.89 | $13.65 |
| Resistance Level | $5.85 | $14.99 |
| Average True Range (ATR) | 0.28 | 0.51 |
| MACD | 0.00 | 0.16 |
| Stochastic Oscillator | 36.99 | 58.59 |
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.